CIHR Funding for Dr. Donald Poirier
SOVAR takes pride in announcing that Dr. Donald Poirier of the Quebec University Hospital Centre (CHU de Québec) has received a $160,000 grant from the Proof of Principle Program (PoP-phase 1) of the Canadian Institutes of Health Research (CIHR).
The funding will be used to optimize the therapeutic potential of aminosteroid derivatives in the fight against ovarian cancer. The disease strikes over 200,000 women worldwide each year and is the 7th most common form of cancer. The drugs currently administered show significant side effects because of their inherent toxicity. A positive outcome from the work underway would open the door to the development of a new drug against ovarian cancer that is more efficient and causes less side effects.
The PoP Program is very competitive and specifically addresses technologies that are solidly grounded in science and that demonstrate a strong market potential.
The grant will enable the further development of the technology and contribute to increasing its value while accelerating its market-readiness.